Oric Pharmaceuticals Inc. Common Stock (ORIC)
Stock · NASDAQ · Health Care
$12.35as of 10/16/2026
Price chart
Active signals
ORIC Signal Track Record
How signals performed across all stocks →What ORIC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +0.6% | 53% | September 18, 2026 |
| Bollinger Band Breakout | 29 | +0.6% | 52% | July 24, 2026 |
| Bollinger Band Breakdown | 18 | -3.1% | 44% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -0.3% | 47% | July 16, 2026 |
| Any 20-session window (baseline) | +1.5% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth fac…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 111
- Website
- oricpharma.com/
Fundamentals
- 1-day range
- $12.04$12.75
- Market cap
- $1.34B
- P/E (trailing)
- —
- P/E (forward)
- -7.38
- EPS (trailing)
- $-1.35
- Dividend yield
- —
- Beta
- 1.13
- Avg. volume
- 1.48M
Forecasts
14 analyst ratings
Oric Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ORICOric Pharmaceuticals Inc. Common Stock$12.35▼ 3.29%Market cap $1.34BP/E —$7.23$14.68
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
- MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$9.55▼ 6.92%Market cap $1.33BP/E —$8.8$23.29
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ORIC Oric Pharmaceuticals Inc. Common Stock | $1.34B | — | $12.35 | ▼ 3.29% | $7.23$14.68 |
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | $1.33B | — | $9.55 | ▼ 6.92% | $8.8$23.29 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26benzinga · 10/14/2026
- BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26Benzinga · 9/23/2026
- ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
- ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 LaunchYahoo · 9/15/2026
Insider Activity
Insider Actions →- Piscitelli Dominic · September 24, 2026 · Option Exercise600 @ $4.36
- Piscitelli Dominic · September 24, 2026 · Sale500 @ $13.51
- Piscitelli Dominic · September 24, 2026 · Sale100 @ $13.5
- Piscitelli Dominic · August 26, 2026 · Option Exercise25.0K @ $6
- Piscitelli Dominic · August 26, 2026 · Option Exercise52.0K @ $4.36
- Piscitelli Dominic · August 26, 2026 · Sale77.0K @ $13.69
- Heyman Richard A. · July 24, 2026 · Option Exercise3.5K @ $1.6
- Heyman Richard A. · July 24, 2026 · Sale6.1K @ $12.02
- Heyman Richard A. · July 24, 2026 · Sale7.0K @ $12.02
- Heyman Richard A. · July 6, 2026 · Sale300 @ $12
Institutional Ownership
March 31, 2026
- Total shares held
- 117.85M
- Total value held
- $1.41B
- Institutional holders
- 175
- Unknown7.16M
- Unknown6.73M
- Unknown5.98M
- Unknown5.82M
- Unknown5.39M
- Unknown4.78M
- Unknown4.51M
- Unknown4.50M
- Unknown4.32M
- Unknown4.12M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
JP Morgan Upgrades ORIC, Raises Target to $26
JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.
JP Morgan Upgrades ORIC, Raises Target to $26. JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.